A Tempe, Arizona-based clinical-stage medical device and biopharmaceutical company is pioneering a novel endovascular treatment designed to stabilize and prevent the rupture of mid-sized abdominal aortic aneurysms a condition affecting over one million Americans annually, with no currently approved therapeutic option for smaller aneurysms beyond watchful waiting. The company's proprietary catheter-based delivery system introduces a stabilizing compound directly to the vessel wall, using a bioactive molecule that cross-links elastin and collagen to strengthen the aortic tissue and inhibit further disease progression. With the product advancing through multiple clinical trial phases and having received FDA Breakthrough Therapy designation, the company's engineering and scientific teams are deeply engaged in qualified R&D work making it an ideal candidate for TaxTaker's R&D credit analysis.

TaxTaker's clinical and technical specialists conducted detailed interviews with the company's research scientists, device engineers, and regulatory professionals to identify qualifying research activities across multiple disciplines. Eligible work included the development and optimization of the dual-balloon delivery catheter, formulation chemistry for the proprietary stabilizing compound, preclinical animal study design and data analysis, clinical trial protocol development, and engineering testing to support IDE and IND submissions to the FDA. Each activity was evaluated against the four-part IRS test, with particular attention to technical uncertainty and the process of experimentation embedded in the company's iterative device development cycle.

The analysis yielded a total of $561,300 in qualifying federal R&D expenses and $141,800 in state-level qualifying expenses, resulting in a combined R&D Tax Credit of approximately $712,200. These credits provided critical non-dilutive funding that enabled the company to continue advancing its stAAAble Phase II/III clinical trial without relying solely on venture financing. The case highlights the significant R&D credit opportunity available to clinical-stage biotech and medical device companies, where the vast majority of spending is inherently experimental and technically uncertain.